| table                                              | row                                | subrow           | Total_new   | Total_benchmark   |
|:---------------------------------------------------|:-----------------------------------|:-----------------|:------------|:-----------------|
| Table A. Treatment Approach                        | First-line therapy¹, n (%)         | Other antivirals | 14          | 13               |
| Table A. Treatment Approach                        | First-line therapy¹, n (%)         | None             | 44          | 6                |
| Table B. Demographics and Clinical Characteristics | Immunosuppressive treatment, n (%) | Anti-CD20        | 77          | 79               |
| Table B. Demographics and Clinical Characteristics | Immunosuppressive treatment, n (%) | CAR-T            | 3           | 4                |
| Table B. Demographics and Clinical Characteristics | Immunosuppressive treatment, n (%) | HSCT             | 3           | 4                |
| Table B. Demographics and Clinical Characteristics | Immunosuppressive treatment, n (%) | Other            |             | 13               |
| Table B. Demographics and Clinical Characteristics | Immunosuppressive treatment, n (%) | Other²           | 13          |                  |
| Table C. Detailed Patient Characteristics          | Autoimmune disease, n (%)          | MS               |             | 2                |
